摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

(2‐isopropylphenyl)magnesium bromide | 63488-08-4

中文名称
——
中文别名
——
英文名称
(2‐isopropylphenyl)magnesium bromide
英文别名
(2-isopropylphenyl)magnesium bromide;2-isopropylphenylmagnesium bromide;o-isopropylphenylmagnesium bromide;bromo(2-(1-methylethyl)phenyl)magnesium;2-(isopropyl)phenyl magnesium bromide
(2‐isopropylphenyl)magnesium bromide化学式
CAS
63488-08-4
化学式
C9H11BrMg
mdl
——
分子量
223.395
InChiKey
STEYSWFFQRBEMS-UHFFFAOYSA-M
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2.45
  • 重原子数:
    11.0
  • 可旋转键数:
    2.0
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.33
  • 拓扑面积:
    0.0
  • 氢给体数:
    0.0
  • 氢受体数:
    0.0

SDS

SDS:ed8bb29ce49b47ce2c656584401a1fd0
查看

反应信息

点击查看最新优质反应信息

文献信息

  • [EN] METAL COMPLEX COMPRISING AMIDINE AND THIOPHENE FUSED CYCLOPENTADIENYL LIGANDS<br/>[FR] COMPLEXE MÉTALLIQUE COMPRENANT DES LIGANDS DE CYCLOPENTADIÉNYLE FUSIONNÉS PAR AMIDINE ET THIOPHÈNE
    申请人:ARLANXEO NETHERLANDS BV
    公开号:WO2019132687A1
    公开(公告)日:2019-07-04
    A metal complex of the formula (1) TCyLMXp (1), wherein M is a group 4 metal Z is an anionic ligand, p is number of 1 to 2, preferably 2, TCy is a thiophene fused cyclopentadienyl-type ligand of the formula (2) wherein R1 and R2 being individually selected from the group of hydrogen, halogen, C1-C10 alkyl, C5-C10 cycloalkyl, and an unsubstituted or C1-C10-alkyl or C1-C4-dialkyl amino substituted С6-С10 aryl, in particular C1-C4-alkyl substituted phenyl and SiR3, OR, NR2, SR, PR2, wherein R means individually C1-C10-alkyl, C5-С10-cycloalkyl, and an unsubstituted or C1-C10-alkyl or C1-C4-dialkyl amino substituted C6-C10-aryl, in particular C1-C4-alkyl substituted phenyl or R1 and R2 together with the 2 double bond carbon atoms of the thiophene ring they are connected to form an unsubstituted or C1-C4-alkyl substituted aliphatic C5-C6-cycloalkene ring, R3, R4 and R5 being individually selected from the group of hydrogen, C1-C4 alkyl, unsubstituted or C1-C4-alkyl and/or halogen, in particular chlorine or fluorine substituted C6-C10-aryl, in particular C1-C4-alkyl substituted phenyl, and SiR3, OR, NR2, SR, PR2, wherein R means individually C1-C10-alkyl, C5-C10-cycloalkyl, and an unsubstituted or C1-C10-alkyl or C1-C4-dialkyl amino substituted C6-C10-aryl, in particular C1-C4-alkyl substituted phenyl and, L is an amidinate ligand of the formula (3) wherein the amidine-containing ligand is covalently bonded to the metal M via the imine nitrogen atom, and Sub1 is an unsubstituted or C1-C4-alkyl and/or halogen, in particular chlorine or fluorine substituted C6-C10-aromatic substituent, in particular phenyl and Sub2 is a substituent comprising a heteroatom of group 15, through which Sub2 is bonded to the imine carbon atom or Sub1 and Sub2 together with the imino group they are connected to form a ligand of formula (3a) wherein the amidine-containing ligand (3a) is covalently bonded to the metal M via the imine nitrogen atom N2, wherein the benzo ring fused to the amidine ring may be unsubstituted or contain further substituents R7, which are individually of the index "q" selected from the group of hydrogen, C1-C4-alkyl and halogen and whereby q is a number of 0 to 4, preferably 0 to 2, most preferably 0, Sub4 is an aliphatic or aromatic cyclic or linear substituent comprising a group 14 atom through which Sub4 is bonded to the amino nitrogen atom N1, preferably Sub4 is a C6-C10 aromatic ring, preferably phenyl which is unsubstituted or substituted by one or more substituents from the group selected from halogen, in particular Cl or F and C1-C4-alkyl.
    一种化学配合物,其化学式为(1)TCyLMXp(1),其中M为4族属,Z为阴离子配体,p为1至2的数字,最好为2,TCy为一种噻吩融合的环戊二烯基型配体,其化学式为(2),其中R1和R2分别选自氢、卤素、C1-C10烷基、C5-C10环烷基、未取代或C1-C10烷基或C1-C4二烷基基取代的C6-C10芳基,特别是C1-C4烷基取代的苯基和SiR3、OR、NR2、SR、PR2,其中R分别表示C1-C10烷基、C5-C10环烷基、未取代或C1-C10烷基或C1-C4二烷基基取代的C6-C10芳基,特别是C1-C4烷基取代的苯基或R1和R2与噻吩环的2个双键碳原子连接在一起形成未取代或C1-C4烷基取代的脂肪族C5-C6环烯基环,R3、R4和R5分别选自氢、C1-C4烷基、未取代或C1-C4烷基和/或卤素,特别是取代的C6-C10芳基,特别是C1-C4烷基取代的苯基和SiR3、OR、NR2、SR、PR2,其中R分别表示C1-C10烷基、C5-C10环烷基、未取代或C1-C10烷基或C1-C4二烷基基取代的C6-C10芳基,特别是C1-C4烷基取代的苯基,L为一种含有酰胺基的配体,其化学式为(3),其中含有酰胺基的配体通过亚胺氮原子与属M共价结合,Sub1为未取代或C1-C4烷基和/或卤素,特别是取代的C6-C10芳基取代基,特别是苯基,Sub2为含有15族元素的取代基,通过该取代基与亚胺碳原子结合或Sub1和Sub2与亚胺基一起形成化学式(3a)的配体,其中含有酰胺基的配体(3a)通过亚胺氮原子N2与属M共价结合,苯环与酰胺环融合的部分可能未取代或含有进一步的取代基R7,该取代基R7分别为指数“q”选自氢、C1-C4烷基和卤素,其中q为0至4的数字,最好为0至2,最好为0,Sub4为含有14族元素的脂肪族或芳香族环状或线性取代基,通过该取代基与基氮原子N1结合,最好Sub4为C6-C10芳香环,最好为苯基,未取代或由卤素(特别是Cl或F)和C1-C4烷基等取代基取代。
  • Multicomponent Coupling Reaction of Perfluoroarenes with 1,3-Butadiene and Aryl Grignard Reagents Promoted by an Anionic Ni(II) Complex
    作者:Takanori Iwasaki、Asuka Fukuoka、Xin Min、Wataru Yokoyama、Hitoshi Kuniyasu、Nobuaki Kambe
    DOI:10.1021/acs.orglett.6b02343
    日期:2016.10.7
    anionic complex as a key intermediate, a regio- and stereoselective multicomponent coupling reaction of perfluoroarenes, aryl Grignard reagents, and 1,3-butadiene in a 1:1:2 ratio was achieved, resulting in the formation of 1,6-octadiene derivatives containing two aryl groups, one from the perfluoroarene and the other from the aryl Grignard reagent, at the 3- and 8-positions, respectively.
    分离出阴离子Ni配合物,并通过X射线晶体学确定其结构。以这种阴离子配合物为关键中间体,全氟芳烃,芳基格氏试剂1,3-丁二烯以1:1:2的比例进行了区域和立体选择性多组分偶联反应,从而形成了1,6 -辛二烯生物在3和8位分别含有两个芳基,一个来自全氟芳烃,另一个来自芳基格氏试剂
  • Use of ER selective NF-kB inhibitors for the treatment of sepsis
    申请人:Caggiano J. Thomas
    公开号:US20050256132A1
    公开(公告)日:2005-11-17
    The present invention provides methods for treating sepsis, systemic inflammatory response syndrome, severe sepsis, septic shock, and multiple organ dysfunction syndrome by modulating NF-κB transcription with ligands that interact with the estrogen receptor, preferably in the absence of classic estrogenic activity. Other aspects of the invention relate to methods for treating sepsis, systemic inflammatory response syndrome, severe sepsis, septic shock, and multiple organ dysfunction syndrome that comprise administering to a patient suffering therefrom an effective amount of a compound of Formula I:
    本发明提供了通过调节与雌激素受体相互作用的配体来调节NF-κB转录,从而治疗脓毒症、全身性炎症反应综合征、严重脓毒症、脓毒性休克和多器官功能障碍综合征的方法,优选在无典型雌激素活性的情况下进行。本发明的其他方面涉及治疗脓毒症、全身性炎症反应综合征、严重脓毒症、脓毒性休克和多器官功能障碍综合征的方法,包括向患有此类病症的患者施用有效量的式I化合物:
  • [EN] BENZODIOXEPINE AND BENZODIOXINE COMPOUNDS THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN FOR THE TREATMENT OF DIABETES<br/>[FR] BENZODIOXÉPINE ET COMPOSÉS DE BENZODIOXINE QUI INTERAGISSENT AVEC LA PROTÉINE RÉGULATRICE DE LA GLUCOKINASE POUR LE TRAITEMENT DU DIABÈTE
    申请人:AMGEN INC
    公开号:WO2012138776A1
    公开(公告)日:2012-10-11
    The present invention relates to compounds of formula I or II, or pharmaceutically acceptable salts thereof, that interact with glucokinase regulatory protein. In addition, the present invention relates to methods of treating type 2 diabetes, and other diseases and/or conditions where glucokinase regulatory protein is involved using the compounds, or pharmaceutically acceptable salts thereof, and pharmaceutical compositions that contain the compounds, or pharmaceutically acceptable salts thereof.
    本发明涉及与葡萄糖激酶调节蛋白相互作用的式I或II的化合物,或其药学上可接受的盐。此外,本发明涉及使用这些化合物或其药学上可接受的盐治疗2型糖尿病和其他涉及葡萄糖激酶调节蛋白的疾病和/或症状的方法,以及含有这些化合物或其药学上可接受的盐的药物组合物。
  • Pd/PC‐Phos‐Catalyzed Enantioselective Intermolecular Denitrogenative Cyclization of Benzotriazoles with Allenes and N‐Allenamides
    作者:Pei‐Chao Zhang、Jie Han、Junliang Zhang
    DOI:10.1002/anie.201904805
    日期:2019.8.12
    Reported herein is an asymmetric Pd/PCPhoscatalyzed denitrogenative cyclization of benzotriazoles with allenes and Nallenamides, representing the first example of enantioselective denitrogenative cyclizations of benzotriazoles. A series of optically active 3‐methyleneindolines were obtained in good yields with high ee values. The use of inexpensive and readily available starting materials, high
    本文报道的是苯并三唑与丙二烯和N-烯酰胺的不对称Pd / PC-Phos催化脱氮环化反应,代表了苯并三唑对映选择性脱氮环化反应的第一个例子。以高收率和高ee 值获得了一系列旋光的3-亚甲基二氢吲哚。使用廉价且容易获得的起始原料,高区域选择性和对映选择性,广泛的底物范围,温和的反应条件,无需碱以及3-亚甲基二氢吲哚的多功能官能化使得该方法具有吸引力。
查看更多

同类化合物

(βS)-β-氨基-4-(4-羟基苯氧基)-3,5-二碘苯甲丙醇 (S,S)-邻甲苯基-DIPAMP (S)-(-)-7'-〔4(S)-(苄基)恶唑-2-基]-7-二(3,5-二-叔丁基苯基)膦基-2,2',3,3'-四氢-1,1-螺二氢茚 (S)-盐酸沙丁胺醇 (S)-3-(叔丁基)-4-(2,6-二甲氧基苯基)-2,3-二氢苯并[d][1,3]氧磷杂环戊二烯 (S)-2,2'-双[双(3,5-三氟甲基苯基)膦基]-4,4',6,6'-四甲氧基联苯 (S)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (R)富马酸托特罗定 (R)-(-)-盐酸尼古地平 (R)-(-)-4,12-双(二苯基膦基)[2.2]对环芳烷(1,5环辛二烯)铑(I)四氟硼酸盐 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[((6-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[(4-叔丁基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[(3-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-(+)-4,7-双(3,5-二-叔丁基苯基)膦基-7“-[(吡啶-2-基甲基)氨基]-2,2”,3,3'-四氢1,1'-螺二茚满 (R)-3-(叔丁基)-4-(2,6-二苯氧基苯基)-2,3-二氢苯并[d][1,3]氧杂磷杂环戊烯 (R)-2-[((二苯基膦基)甲基]吡咯烷 (R)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (N-(4-甲氧基苯基)-N-甲基-3-(1-哌啶基)丙-2-烯酰胺) (5-溴-2-羟基苯基)-4-氯苯甲酮 (5-溴-2-氯苯基)(4-羟基苯基)甲酮 (5-氧代-3-苯基-2,5-二氢-1,2,3,4-oxatriazol-3-鎓) (4S,5R)-4-甲基-5-苯基-1,2,3-氧代噻唑烷-2,2-二氧化物-3-羧酸叔丁酯 (4S,4''S)-2,2''-亚环戊基双[4,5-二氢-4-(苯甲基)恶唑] (4-溴苯基)-[2-氟-4-[6-[甲基(丙-2-烯基)氨基]己氧基]苯基]甲酮 (4-丁氧基苯甲基)三苯基溴化磷 (3aR,8aR)-(-)-4,4,8,8-四(3,5-二甲基苯基)四氢-2,2-二甲基-6-苯基-1,3-二氧戊环[4,5-e]二恶唑磷 (3aR,6aS)-5-氧代六氢环戊基[c]吡咯-2(1H)-羧酸酯 (2Z)-3-[[(4-氯苯基)氨基]-2-氰基丙烯酸乙酯 (2S,3S,5S)-5-(叔丁氧基甲酰氨基)-2-(N-5-噻唑基-甲氧羰基)氨基-1,6-二苯基-3-羟基己烷 (2S,2''S,3S,3''S)-3,3''-二叔丁基-4,4''-双(2,6-二甲氧基苯基)-2,2'',3,3''-四氢-2,2''-联苯并[d][1,3]氧杂磷杂戊环 (2S)-(-)-2-{[[[[3,5-双(氟代甲基)苯基]氨基]硫代甲基]氨基}-N-(二苯基甲基)-N,3,3-三甲基丁酰胺 (2S)-2-[[[[[((1S,2S)-2-氨基环己基]氨基]硫代甲基]氨基]-N-(二苯甲基)-N,3,3-三甲基丁酰胺 (2S)-2-[[[[[[((1R,2R)-2-氨基环己基]氨基]硫代甲基]氨基]-N-(二苯甲基)-N,3,3-三甲基丁酰胺 (2-硝基苯基)磷酸三酰胺 (2,6-二氯苯基)乙酰氯 (2,3-二甲氧基-5-甲基苯基)硼酸 (1S,2S,3S,5S)-5-叠氮基-3-(苯基甲氧基)-2-[(苯基甲氧基)甲基]环戊醇 (1S,2S,3R,5R)-2-(苄氧基)甲基-6-氧杂双环[3.1.0]己-3-醇 (1-(4-氟苯基)环丙基)甲胺盐酸盐 (1-(3-溴苯基)环丁基)甲胺盐酸盐 (1-(2-氯苯基)环丁基)甲胺盐酸盐 (1-(2-氟苯基)环丙基)甲胺盐酸盐 (1-(2,6-二氟苯基)环丙基)甲胺盐酸盐 (-)-去甲基西布曲明 龙蒿油 龙胆酸钠 龙胆酸叔丁酯 龙胆酸 龙胆紫-d6 龙胆紫